Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Veru Inc. Q1 FY2026 Earnings Call - Regulatory clarity for enobosarm, Phase 2b PLATEAU to test fat-selective weight loss and muscle/bone preservation
Veru used the quarter to sell a clear regulatory roadmap for enobosarm as a combo with GLP-1 therapy and to tee up a 200-patient Phase 2b PLATEAU study aimed at older patients with severe obesity. The...
- FDA meeting provided regulatory clarity for enobosarm as adjunct to GLP-1 therapy, with two acceptable approval pathways: a >=5% placebo-corrected incremental weight loss at 52 weeks of maintenance, or clinically meaningful preservation/improvement in physical function or other endpoints if incremental weight loss is <5%.
- FDA confirmed enobosarm 3 mg is an acceptable dose for future clinical development.
- Veru completed a positive Phase 2b QUALITY study in 168 older patients showing enobosarm combined with semaglutide preserved lean mass, improved fat loss selectivity, and reduced regain after semaglutide discontinuation, providing proof of concept.
- +12 more takeaways
NetEase Q4 2025 Earnings Call - AI Integration Becomes Core Productivity and Gameplay Multiplier
NetEase closed 2025 with steady top-line growth and a clear strategic pivot: AI is now embedded across development, QA, art, and gameplay, and management argues that vertical, game-specific models and...
- Total 2025 net revenue CNY 112.6 billion, up 10% year-over-year; Q4 revenue CNY 27.5 billion.
- Games and value-added services generated CNY 92.1 billion in 2025, up 10% YoY; online games revenue was CNY 89.6 billion, up 11% YoY.
- Q4 online games revenue rose 4% YoY to CNY 21.3 billion, with QoQ seasonality noted versus a stronger summer quarter.
- +15 more takeaways
Kraft Heinz Q4 2025 Earnings Call - CEO Pauses Separation, Committing $600M to Jumpstart Volume-Led Recovery
Kraft Heinz closed a bruising 2025 with material share losses and margin pressure, but converted that damage into cash. Full-year adjusted EPS fell to $2.60, down 15% year over year, and organic net s...
- CEO Steve Cahillane pauses the planned separation, citing tougher market conditions and a need to restore business momentum before revisiting structural moves.
- Management will deploy approximately $600 million of incremental investment in 2026 to drive a volume-led, profitable recovery, funded from strong free cash flow and a healthy balance sheet.
- 2025 adjusted EPS was $2.60, a 15% decline versus 2024, driven by share losses, margin pressure, higher tax rate, and increased interest expense.
- +14 more takeaways
Youdao Q4 2025 Earnings Call - AI subscriptions and ads drive growth and first full-year positive operating cash flow
Youdao closed 2025 with a clear AI-native narrative backed by numbers. Q4 revenues rose 16.8% year-over-year to RMB 1.6 billion, powered by a return to growth in learning services and strong online ma...
- Q4 net revenue RMB 1.6 billion, up 16.8% year-over-year, led by learning services and online marketing gains.
- Full year 2025 revenue RMB 5.9 billion, up 5% year-over-year; operating profit rose 48.7% to RMB 221.3 million.
- Youdao delivered its first full year of positive operating cash flow, RMB 55.2 million, versus a RMB 67.9 million outflow in 2024; Q4 operating cash inflow was RMB 184.2 million.
- +13 more takeaways
Robinhood Q4 and Full-Year 2025 Earnings Call - Product Velocity Turns into Diversified, Profitable Growth
Robinhood closed 2025 with a clean set of numbers and a loud strategic pivot from single-product growth to a multi-armed financial super app. Management delivered record revenue of $4.5 billion, adjus...
- Record 2025 financials, revenues $4.5 billion, up 52% year-over-year, adjusted EBITDA $2.5 billion with a 56% adjusted EBITDA margin.
- Total platform assets grew nearly 70% year-over-year to $324 billion, with $68 billion of net deposits for 2025 and a record Q4 net deposits of $16 billion.
- Q4 revenue was a record $1.3 billion, and management reported strong start to 2026 with equity volumes +50% YoY and options +20% YoY in January.
- +12 more takeaways
Mattel, Inc. Fourth Quarter 2025 Earnings Call - Buys Mattel163; $150M Reinvestment Hits 2026, Targets 2027 Payoff
Mattel closed 2025 with a mixed finish: Q4 gross billings grew 6% and POS was positive across all regions, but U.S. December softness left the company below its full year expectations. Management is d...
- Mattel reported Q4 gross billings up 6% year-over-year, with North America +7% and international +4% in constant currency, but U.S. December growth missed expectations and weighed on full year results.
- Point of sale (POS) was positive across all regions and roughly +3% for both the quarter and full year, indicating demand existed even as U.S. retail ordering patterns shifted.
- Mattel agreed to acquire NetEase’s 50% interest in Mattel163 for $159 million, valuing the JV at $380 million; Mattel163 has ~20 million monthly active users and ~550 million downloads to date.
- +11 more takeaways
James Hardie Q3 FY2026 Earnings Call - Integration Momentum: Synergies on Track as Company Lays Groundwork for FY2027 Margin Recovery
James Hardie reported a solid Q3, beating guidance with total net sales of $1.24 billion, driven by the AZEK acquisition and modest organic growth. Management stressed that execution and commercial mo...
- Total net sales rose 30% to $1.24 billion in Q3, which included $275 million of acquired AZEK sales; organic sales were up about 1%.
- Adjusted EBITDA for the quarter was $330 million, with an adjusted EBITDA margin of 26.6%.
- Siding and Trim adjusted EBITDA was $269 million with a 34.1% margin, a near 500 basis point sequential improvement driven largely by price and mix.
- +12 more takeaways
Astera Labs Q4 2025 Earnings Call - Hyperscaler Validation and $6.5B Amazon Warrant, But Big OpEx and Execution Stretch Ahead
Astera Labs closed out FY2025 with heavy acceleration: Q4 revenue of $270.6 million (up 17% q/q, 92% y/y) and full-year revenue of $852.5 million (up 115% y/y). Management pointed to broad-based stren...
- Q4 2025 revenue $270.6M, up 17% sequentially and 92% year-over-year; FY2025 revenue $852.5M, up 115% y/y.
- Scorpio P-Series continued a volume ramp at the lead customer and exceeded management’s target (Scorpio P >10% of revenue for the year); management claims it is the only PCIe 6 fabric shipping in volume today.
- Scorpio X-Series shipped pre-production quantities in Q4; initial shipments to additional hyperscalers expected in H2 2026 with volume ramps set for 2027; engaged with 10+ customers for X family.
- +15 more takeaways
Exelixis Fourth Quarter and Fiscal Year 2025 Earnings Call - Zanzalintinib NDA Accepted; CABOMETYX Keeps Momentum
Exelixis closed 2025 with a clean slice of momentum, driven by CABOMETYX market strength and a regulatory milestone that could reshape the company. CABO posted robust growth, with US franchise net pro...
- FDA accepted the NDA for zanzalintinib plus atezolizumab in third-line-plus colorectal cancer, PDUFA date set for December 3, 2026.
- STELLAR-303 met one of its dual primary endpoints, showing a 20% reduction in risk of death in the ITT population; non-liver-metastases (NLM) OS data were favorable but immature, with a final analysis expected mid-2026.
- Exelixis plans an aggressive zanzalintinib development program, with seven ongoing or planned pivotal trials and additional combination discussions underway, signaling intent to build a second oncology franchise.
- +11 more takeaways
Insperity Fourth Quarter 2025 Earnings Call - Margin recovery underway, HRScale to seed 2027 growth
Insperity closed 2025 with weak near-term profitability but a clear, deliberate pivot to margin recovery. Q4 adjusted EPS was negative $0.60 and adjusted EBITDA was negative $13 million, though exclud...
- Q4 adjusted EPS was negative $0.60 and adjusted EBITDA was negative $13 million; excluding a $2.8 million accelerated office consolidation charge adjusted EPS improves to negative $0.54 and adjusted EBITDA to negative $11 million.
- Average paid worksite employees (WSE) in Q4 were 312,377, a 1.1% increase over Q4 2024, but slightly below forecast due to client net hiring volatility and a weaker November.
- Gross profit per WSE in Q4 was $183 per month, generally in line with guidance; benefit costs were elevated from healthcare claims development but partially offset by favorability in other benefits, workers compensation, and payroll tax.
- +16 more takeaways